Dr. Levy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave # 1286
Box 1270
San Francisco, CA 94143Phone+1 415-443-9673Fax+1 415-476-0624
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2008
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2004 - 2006
University of Michigan Medical SchoolClass of 2004
Certifications & Licensure
CA State Medical License 2005 - 2027- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable Start of enrollment: 2007 Oct 01
- A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable Start of enrollment: 2008 Mar 01
- A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2009 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsEffect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.Anna Kiialainen, Markus Niggli, Christine L Kempton, Giancarlo Castaman, Tiffany Chang
Haemophilia. 2022-11-01 - 4 citationsUntreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.Michael U Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu
Research and Practice in Thrombosis and Haemostasis. 2022-08-01 - 5 citationsA Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients with Hemophilia AKoichiro Yoneyama, Christophe Schmitt, Tiffany Chang, Christophe Dhalluin, Sayaka Nagami
Journal of Clinical Pharmacology. 2021-09-21
Journal Articles
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without InhibitorsChristine Kempton, Gallia G Levy, Michael U Callaghan, The New England Journal of Medicine
Authored Content
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsJuly 2017
Press Mentions
Long-Term Data Reinforce SPK-8011 Gene Therapy’s Potential for Hem AJanuary 6th, 2023- Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical OfficerAugust 10th, 2020
FDA Expands Approval of Roche Hemophilia DrugOctober 4th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
